Predictors of Mucosal Healing in Ulcerative Colitis: A Post-hoc Analysis of VARSITY

Narrative Summary
There is a need for predictor(s) of mucosal healing in patients with Inflammatory Bowel Disease (IBD), in particular with ulcerative colitis, to improve long-term patient outcomes (3). This study aims to identify possible early predictor(s) for mucosal healing in ulcerative colitis from the VARSITY trial, data accessed through VIVLI.

Participants
The participants include those subjects who participated in the VARSITY TRIAL. This study enrolled 771 people, of whom 769 received at least one dose of treatment, either vedolizumab (383 participants) or adalimumab (386 participants) (1).

Research Methods
The proposed research is a post-hoc review of the VARSITY trial data to identify predictor(s) at baseline and week 14 for achieving mucosal healing at week 52 in the study (1).

Study Design
The VARSITY trial was a randomized, double-blind, active-controlled trial with two medication treatment groups (vedolizumab or adalimumab) from July 2015 to January 2019 at 245 sites in 34 countries. Inclusion criteria included patients ages 18 to 85 with moderate to severe active ulcerative colitis. This post-hoc analysis aims to evaluate predictors of mucosal healing at week 52 utilizing data including clinical laboratory test results (i.e. fecal calprotectin, a biomarker measurement of inflammation), and a disease activity index for ulcerative colitis referred to as the Mayo scale that includes endoscopic scores evaluated by physicians utilizing imaging of endoscopic procedures read at a central location and patient reported outcomes (i.e stool frequency and rectal bleeding) from baseline and week 14.